2,5-bis(1-aziridinyl)-3,6-bis(2-methoxyethoxy)-4-benzoquinone has been researched along with Lung Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aisner, J; Carney, D; Fuks, JZ; Ihde, DC; Levitt, M; Van Echo, DA; Wiernik, PH | 1 |
| Anbar, D; Booth, BW; Capizzi, RL; Carey, RW; Comis, RL; Green, M; Kennedy, BJ; Raich, PC; Shulman, P | 1 |
| Baker, LH; Haas, CD; Leichman, LP; Schilcher, RB; Young, JD | 1 |
3 other study(ies) available for 2,5-bis(1-aziridinyl)-3,6-bis(2-methoxyethoxy)-4-benzoquinone and Lung Neoplasms
| Article | Year |
|---|---|
Phase II trial of aziridinylbenzoquinone (AZQ) in patients with refractory small cell carcinoma of the lung.
Topics: Adult; Aged; Antineoplastic Agents; Aziridines; Azirines; Benzoquinones; Carcinoma, Small Cell; Cyclohexenes; Drug Administration Schedule; Drug Evaluation; Female; Humans; Lung Neoplasms; Male; Middle Aged | 1983 |
Cancer and leukemia group B phase II non-small cell lung carcinoma trial: aziridinylbenzoquinone (AZQ).
Topics: Anemia; Aziridines; Azirines; Benzoquinones; Cyclohexenes; Drug Evaluation; Female; Humans; Leukemia; Lung Neoplasms; Male; Middle Aged; Prognosis | 1983 |
Phase I evaluation and pharmacokinetics of aziridinylbenzoquinone using a weekly intravenous schedule.
Topics: Antineoplastic Agents; Aziridines; Azirines; Benzoquinones; Colonic Neoplasms; Cyclohexenes; Drug Administration Schedule; Drug Evaluation; Humans; Kidney Neoplasms; Kinetics; Liver Neoplasms; Lung Neoplasms; Male; Melanoma; Testicular Neoplasms | 1983 |